Back to search results

[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD

Abroad (travel likely)RecruitingPHASE2, PHASE3

Conditions

Parkinson Disease · Dementia With Lewy Bodies · MSA - Multiple System Atrophy · Alzheimer Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • UZ Ghent, Ghent, Gent, Belgium

    Contact: Study coordinator (Donatienne Van Weehaeghe, Dr.) · donatienne.vanweehaeghe@uzgent.be · +32 9 332 30 27
    Contact: Principal Investigator (Donatienne Van Weehaeghe, Dr.)
    Patrick Santens, Prof. dr. (Sub-investigator)
    Tim Van Langenhove, Dr. (Sub-investigator)

  • UZ Leuven, Leuven, Vlaams-Brabant, Belgium

    Contact: Study coordinator (Koen Van Laere, Prof. dr.) · koen.vanlaere@UZLeuven.be · +3216343715
    Contact: Principal Investigator (Koen Van Laere, Prof. Dr.)
    Wim Vandenberghe, Prof. Dr. (Sub-investigator)
    Aline Delva, Dr. (Sub-investigator)
    Louis Versweyveld, Dr. (Sub-investigator)
Study leads

  • Koen Van Laere

    Principal Investigator

    Professor at KULeuven, department head of nuclear medicine at UZ Leuven

View source on ClinicalTrials.gov(opens in a new tab)Contact study team (email)